Evidence map›Paper›PMID 34816130›Full record

ArticleJAAD international2021

Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis.

Helen Y Sun, Elena Keller, Harish Suresh, Deshan F Sebaratnam

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAAD international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Helen Y SunFaculty of Medicine and Health, The University of New South Wales, Kensington, New South Wales, Australia.
Elena KellerCentre for Big Data Research in Health, The University of New South Wales, Kensington, New South Wales, Australia.
Harish SureshFaculty of Business, The University of New South Wales, Kensington, New South Wales, Australia.
Deshan F SebaratnamFaculty of Medicine and Health, The University of New South Wales, Kensington, New South Wales, Australia.
UNSW Sydney · AULiverpool Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiologics are a good therapeutic option for severe, chronic plaque psoriasis; however, they come with significant cost to the health care system.

objectiveTo conduct a cost-utility analysis of outpatient biologics (adalimumab, etanercept, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab, and ustekinumab) available to adults with severe, chronic plaque psoriasis from the perspective of the Australian health care system.

methodsA Markov cohort model was constructed to estimate the quality-adjusted life years (QALYs) and costs accrued for treatment pathways commencing with different first-line biologics, over a 96-week time horizon. The model adhered to the Australian Pharmaceutical Benefits Scheme eligibility criteria and guidelines.

resultsA biologic treatment pathway commencing on tildrakizumab was the most cost-effective first-line treatment (Australian dollar 39,930; total utility of 1.57 QALYs over 96 weeks). First-line secukinumab and risankizumab had incremental cost-utility ratios of Australian dollar 194,524/QALY and Australian dollar 479,834/QALY, respectively, when compared with first-line tildrakizumab. LIMITATIONS: The efficacy and utility input parameters were derived from international randomized control trials and patients from the United Kingdom, respectively. Findings from this study cannot be generalized beyond Australia.

conclusionTildrakizumab may be considered as first-line treatment for adult patients with severe, chronic plaque psoriasis embarking on biologic therapy, from the economic perspective of the Australian health care system.

Indexed as

adalimumabAUD, Australian dollarAustraliabiologic therapyBSC, best supportive careCI, confidence intervalcost-benefit analysiscost-effectiveness analysiscost-utility analysiscyclosporinedermatologistsetanerceptguselkumabhealth economicsICUR, incremental cost-utility ratioIL, interleukininfliximabixekizumabPASI75, 75% improvement from the initial Psoriasis Area and Severity Index ScorePASI, Psoriasis Area and Severity IndexPBS, Pharmaceutical Benefits SchemepsoriasisQALY, quality-adjusted life yearsquality of lifeRCT, randomized-controlled trialrisankizumabtildrakizumabTNF-α, tumor necrosis alphaWTP, willingness-to-pay

Identifiers

PMID34816130
PMCPMC8593743
OpenAlexW3193248995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.